AR039388A1 - Formulaciones liquidas de baja dosis de entecavir y uso - Google Patents
Formulaciones liquidas de baja dosis de entecavir y usoInfo
- Publication number
- AR039388A1 AR039388A1 ARP030101211A ARP030101211A AR039388A1 AR 039388 A1 AR039388 A1 AR 039388A1 AR P030101211 A ARP030101211 A AR P030101211A AR P030101211 A ARP030101211 A AR P030101211A AR 039388 A1 AR039388 A1 AR 039388A1
- Authority
- AR
- Argentina
- Prior art keywords
- entecavir
- composition
- low
- liquid
- formulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan composiciones farmacéuticas líquidas, que tienen una baja dosis de entecavir. En una modalidad de la composición líquida de entecavir es una composición lista para usar que está formulada para ser a la vez estable y de sabor agradable. En una segunda modalidad la composición líquida de entecavir está formulada de una composición en polvo en el momento de uso. Las composiciones de baja dosis de entecavir pueden también incluir por lo menos un componente seleccionado de edulcorante, conservador, agente saborizante, agente de solución amortiguador, o combinaciones de éstos. Las composiciones líquidas de entecavir pueden también ser formuladas en combinación con otros agentes farmacéuticamente activos. Reivindicación 1: Una composición farmacéutica líquida para tratar infecciones por el virus de hepatitis B, que comprende un solvente farmacéuticamente aceptable y alrededor de 0,001% hasta alrededor de 20% p/v de entecavir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37067402P | 2002-04-08 | 2002-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039388A1 true AR039388A1 (es) | 2005-02-16 |
Family
ID=29250568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101211A AR039388A1 (es) | 2002-04-08 | 2003-04-07 | Formulaciones liquidas de baja dosis de entecavir y uso |
Country Status (22)
Country | Link |
---|---|
US (1) | US20030190334A1 (es) |
EP (1) | EP1492510A4 (es) |
JP (1) | JP2005528389A (es) |
KR (1) | KR20040099403A (es) |
CN (1) | CN1319517C (es) |
AR (1) | AR039388A1 (es) |
AU (1) | AU2003226259A1 (es) |
BR (1) | BR0309057A (es) |
CA (1) | CA2481092A1 (es) |
EA (1) | EA008102B1 (es) |
EC (1) | ECSP045349A (es) |
HR (1) | HRP20040893A2 (es) |
MX (1) | MXPA04009735A (es) |
MY (1) | MY131488A (es) |
NO (1) | NO20044451L (es) |
NZ (1) | NZ535535A (es) |
PE (1) | PE20040324A1 (es) |
PL (1) | PL372322A1 (es) |
RS (1) | RS88404A (es) |
TW (1) | TWI275392B (es) |
WO (1) | WO2003086367A1 (es) |
ZA (1) | ZA200407672B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7511139B2 (en) | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
CN1732944B (zh) * | 2005-09-02 | 2013-05-08 | 海南中和药业有限公司 | 恩替卡韦分散片及其制备方法 |
US20070060599A1 (en) * | 2005-09-09 | 2007-03-15 | Dimarco John D | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
RU2381807C1 (ru) * | 2008-07-18 | 2010-02-20 | Алексей Глебович Одинец | Противовирусное средство |
CN101869569A (zh) * | 2009-04-21 | 2010-10-27 | 李迪 | 即用型恩替卡韦组合物 |
EP2508172A1 (en) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
AU2012296622C1 (en) | 2011-08-16 | 2017-02-16 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
CN102908312B (zh) * | 2011-11-10 | 2014-06-04 | 陈小花 | 抗乙肝病毒液体组合物 |
US8517850B1 (en) * | 2012-12-11 | 2013-08-27 | Cobra Golf Incorporated | Golf club grip with device housing |
KR101462018B1 (ko) * | 2013-04-01 | 2014-11-19 | 썬시스템즈(주) | 엔테카비르 함유 구강 붕해형 필름제제 |
CN103301071A (zh) * | 2013-06-03 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法 |
US20160175313A1 (en) * | 2013-08-06 | 2016-06-23 | Dongkook Pharmaceutical Co., Ltd., | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
CN106573003B (zh) * | 2014-06-20 | 2022-04-01 | 西梯茜生命工学股份有限公司 | 含有恩替卡韦作为活性成分的药物制剂及其制备方法 |
CN104083374A (zh) * | 2014-07-18 | 2014-10-08 | 石家庄创建医药科技有限公司 | 一种恩替卡韦口服液组合物 |
CN109984996B (zh) * | 2018-01-02 | 2022-01-18 | 扬子江药业集团有限公司 | 恩替卡韦口服溶液及其制备方法 |
CN108434096A (zh) * | 2018-06-20 | 2018-08-24 | 广州大光制药有限公司 | 一种恩替卡韦口服溶液及其制备方法 |
AU2019293579A1 (en) * | 2018-06-29 | 2021-01-07 | The Doshisha | Formulation containing emricasan |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
CZ20012544A3 (cs) * | 1999-01-12 | 2002-01-16 | Smithkline Beecham Biologicals S.A. | Farmaceutické balení |
HU230698B1 (hu) * | 2000-02-29 | 2017-09-28 | Bristol-Myers Squibb Holdings Ireland | Alacsony dózisú entecavir formuláció és alkalmazása |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
-
2003
- 2003-04-02 TW TW092107553A patent/TWI275392B/zh not_active IP Right Cessation
- 2003-04-02 MY MYPI20031228A patent/MY131488A/en unknown
- 2003-04-03 CN CNB038132877A patent/CN1319517C/zh not_active Expired - Fee Related
- 2003-04-03 MX MXPA04009735A patent/MXPA04009735A/es not_active Application Discontinuation
- 2003-04-03 EA EA200401298A patent/EA008102B1/ru not_active IP Right Cessation
- 2003-04-03 KR KR10-2004-7015936A patent/KR20040099403A/ko not_active Application Discontinuation
- 2003-04-03 AU AU2003226259A patent/AU2003226259A1/en not_active Abandoned
- 2003-04-03 NZ NZ535535A patent/NZ535535A/en unknown
- 2003-04-03 WO PCT/US2003/010371 patent/WO2003086367A1/en active Application Filing
- 2003-04-03 CA CA002481092A patent/CA2481092A1/en not_active Abandoned
- 2003-04-03 EP EP03746598A patent/EP1492510A4/en not_active Withdrawn
- 2003-04-03 JP JP2003583388A patent/JP2005528389A/ja active Pending
- 2003-04-03 PL PL03372322A patent/PL372322A1/xx unknown
- 2003-04-03 BR BR0309057-4A patent/BR0309057A/pt not_active IP Right Cessation
- 2003-04-03 RS YU88404A patent/RS88404A/sr unknown
- 2003-04-04 US US10/407,287 patent/US20030190334A1/en not_active Abandoned
- 2003-04-07 AR ARP030101211A patent/AR039388A1/es not_active Application Discontinuation
- 2003-04-08 PE PE2003000351A patent/PE20040324A1/es not_active Application Discontinuation
-
2004
- 2004-09-22 ZA ZA200407672A patent/ZA200407672B/en unknown
- 2004-09-29 HR HR20040893A patent/HRP20040893A2/hr not_active Application Discontinuation
- 2004-10-08 EC EC2004005349A patent/ECSP045349A/es unknown
- 2004-10-19 NO NO20044451A patent/NO20044451L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1492510A4 (en) | 2006-01-11 |
HRP20040893A2 (en) | 2005-02-28 |
TW200306840A (en) | 2003-12-01 |
ZA200407672B (en) | 2005-10-12 |
AU2003226259A1 (en) | 2003-10-27 |
EA008102B1 (ru) | 2007-04-27 |
CN1319517C (zh) | 2007-06-06 |
CN1658844A (zh) | 2005-08-24 |
EA200401298A1 (ru) | 2005-02-24 |
US20030190334A1 (en) | 2003-10-09 |
MXPA04009735A (es) | 2005-01-11 |
RS88404A (en) | 2006-12-15 |
BR0309057A (pt) | 2005-02-01 |
TWI275392B (en) | 2007-03-11 |
EP1492510A1 (en) | 2005-01-05 |
PL372322A1 (en) | 2005-07-11 |
CA2481092A1 (en) | 2003-10-23 |
NZ535535A (en) | 2006-09-29 |
MY131488A (en) | 2007-08-30 |
JP2005528389A (ja) | 2005-09-22 |
PE20040324A1 (es) | 2004-05-29 |
KR20040099403A (ko) | 2004-11-26 |
ECSP045349A (es) | 2005-01-03 |
WO2003086367A1 (en) | 2003-10-23 |
NO20044451L (no) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039388A1 (es) | Formulaciones liquidas de baja dosis de entecavir y uso | |
DE60019902D1 (de) | Echinocandin pharmazeutische zusammensetzungen | |
HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
BR0108435A (pt) | Formulação e uso de entecavir de baixa dose | |
EA200601467A1 (ru) | Макроциклические соединения в качестве ингибиторов вирусной репликации | |
ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
CY1112523T1 (el) | Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο | |
RS114004A (en) | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
MX9400801A (es) | Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon. | |
HUP0301506A2 (hu) | Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére | |
BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
ATE324112T1 (de) | Topische behandlung bei der mastalgie | |
BR0306923A (pt) | Composição farmacêutica para regeneração de tecidos hepáticos para tratamento de cirrose do fìgado uso de 5-(2-pirazinil) -4-metil-1,2-ditiol-3-tiona | |
ES2129448T3 (es) | Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas. | |
AR042598A1 (es) | Composiciones de acetaminofeno | |
UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
WO2003026570A3 (en) | Reduced toxicity cisplatin formulations and methods for using the same | |
AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
TR200302027T4 (tr) | Hayvanlarda görülen parazit kaynaklı hastalıkarın tedavisine yönelik ilaç kompozisyonları | |
SE0203817D0 (sv) | New composition | |
BR0108732A (pt) | Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática | |
DE60031385D1 (de) | Pharmazeutische Zusammensetzungen von Antibiotika und Fruktan-Gemische | |
BRPI0418798A (pt) | métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit | |
DE69902925D1 (de) | Ramoplaninhaltige neue injizierbare arzneizubereitungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |